Literature DB >> 28346399

Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

Peter J Wermuth1, Kellan R Carney1, Fabian A Mendoza2, Sonsoles Piera-Velazquez1, Sergio A Jimenez1.   

Abstract

In this study, we tested the hypothesis that constitutive endothelial cell-specific activation of TGF-β signaling induces tissue fibrosis and vasculopathy resembling the characteristic fibrotic and vascular alterations of systemic sclerosis. Transgenic mice with inducible expression of a constitutively active TGF-β receptor I specifically in endothelial cells were generated by intercrossing mice harboring a constitutively active TGF-β receptor I with a mouse strain containing the endothelial cell-specific Cdh5 gene promoter directing the tamoxifen-inducible expression of the Cre-ERT2 cassette. Administration of tamoxifen to these mice would result in constitutive TGF-β activation and signaling confined to endothelial lineage cells. The effects of constitutive TGF-β endothelial cell activation were assessed by histopathological examination of skin and various internal organs, tissue hydroxyproline analysis, and assessment of expression of myofibroblast differentiation and TGF-β signaling genes employing real-time PCR and immunohistochemical staining of lung vessels for endothelial- and myofibroblast-specific proteins. Constitutive TGFβ-1 signaling in endothelial cells resulted in cutaneous and visceral fibrosis with prominent fibrotic involvement of the lungs and severe perivascular and subendothelial fibrosis of small arterioles. A marked increase in the expression of fibrosis-associated genes and of genes indicative of myofibroblast activation was also found. Confocal microscopy of lung vessels showed evidence consistent with the induction of endothelial-to-mesenchymal transition (EndoMT). Taken together, our data indicate that transgenic mice with constitutive endothelial cell-specific activation of TGF-β signaling display severe cutaneous, pulmonary, and microvascular fibrosis resembling the fibrotic and microvascular alterations characteristic of systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346399      PMCID: PMC6530474          DOI: 10.1038/labinvest.2017.23

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  40 in total

Review 1.  Fibroblasts and myofibroblasts: their source, function and role in disease.

Authors:  Robin J McAnulty
Journal:  Int J Biochem Cell Biol       Date:  2006-11-23       Impact factor: 5.085

Review 2.  Update on systemic sclerosis.

Authors:  Courtney J McCray; Maureen D Mayes
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 3.  Review: evidence that systemic sclerosis is a vascular disease.

Authors:  Marco Matucci-Cerinic; Bashar Kahaleh; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2013-08

Review 4.  Crosstalk between fibroblasts and inflammatory cells.

Authors:  Sophie Van Linthout; Kapka Miteva; Carsten Tschöpe
Journal:  Cardiovasc Res       Date:  2014-04-11       Impact factor: 10.787

Review 5.  Determination of hydroxyproline.

Authors:  H Stegemann; K Stalder
Journal:  Clin Chim Acta       Date:  1967-11       Impact factor: 3.786

6.  An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.

Authors:  Jaspreet Pannu; Elizabeth Gore-Hyer; Masayoshi Yamanaka; Edwin A Smith; Semyon Rubinchik; Jian-Yun Dong; Stefania Jablonska; Maria Blaszczyk; Maria Trojanowska
Journal:  Arthritis Rheum       Date:  2004-05

7.  Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Fabian A Mendoza; Sonsoles Piera-Velazquez; John L Farber; Carol Feghali-Bostwick; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

8.  Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts.

Authors:  J Varga; J Rosenbloom; S A Jimenez
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

9.  Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.

Authors:  Francesco Del Galdo; Federica Sotgia; Cecilia J de Almeida; Jean-Francois Jasmin; Megan Musick; Michael P Lisanti; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2008-09

Review 10.  The pathology of scleroderma vascular disease.

Authors:  Jo Nadine Fleming; Stephen Mark Schwartz
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

View more
  4 in total

1.  Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4.

Authors:  Peter J Wermuth; Fabian A Mendoza; Sergio A Jimenez
Journal:  Lab Invest       Date:  2018-11-23       Impact factor: 5.662

Review 2.  New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.

Authors:  Eloisa Romano; Irene Rosa; Bianca Saveria Fioretto; Marco Matucci-Cerinic; Mirko Manetti
Journal:  Life (Basel)       Date:  2021-06-24

3.  Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study.

Authors:  Tom Gyllenhammar; Mikael Kanski; Henrik Engblom; Dirk M Wuttge; Marcus Carlsson; Roger Hesselstrand; Håkan Arheden
Journal:  BMC Cardiovasc Disord       Date:  2018-01-30       Impact factor: 2.298

Review 4.  A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis.

Authors:  Duong Thi Bich Thuan; Hatem Zayed; Ali H Eid; Haissam Abou-Saleh; Gheyath K Nasrallah; Arduino A Mangoni; Gianfranco Pintus
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.